Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
57°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
August 30, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces New Chief Business Innovation Officer
August 26, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
August 26, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
August 25, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
August 23, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer to Acquire Trillium Therapeutics Inc.
August 23, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
August 20, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Prices $1.0 Billion Sustainability Bond
August 16, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
August 16, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine
August 13, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata
August 04, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
PFIZER REPORTS SECOND-QUARTER 2021 RESULTS
July 28, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
July 23, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings
July 21, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa
July 21, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Announces New Investor Relations Leader
July 19, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Third-Quarter 2021 Dividend
June 24, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
June 23, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
June 16, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts
June 16, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
June 10, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
June 08, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults
May 24, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®
May 20, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
May 10, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID-19 Vaccine
May 07, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
May 06, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
May 04, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
April 28, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Acquires Amplyx Pharmaceuticals
April 28, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.